Sino Biopharm jumps on positive cancer drug trial results

Sino Biopharmaceutical

17/07/2024 07:15

** Shares of Sino Biopharmaceutical  1177.HK  jump 5.3% to
HK$2.97, their highest since May 23
    ** Stock on track for the biggest one-day pct rise since 
May 9
    ** Co announces positive results of phase III clinical study
of anlotinib hydrochloride capsule in combination with
chemotherapy for first-line treatment of advanced soft tissue
sarcoma
    ** Adds, it has obtained consent of Centre for Drug
Evaluation of China's National Medical Products Administration
to submit a marketing application and it will submit the
application in the near future
    ** Hang Seng Commerce & Industry Index  .HSNC  climbs 0.2%,
healthcare index  .HSCIH  rises 2.8% and Hang Seng Index  .HSI 
adds 0.4%
    ** Stock down 14.4% YTD  

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))